Market Closed -
Japan Exchange
07:00:00 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
459
JPY
|
-1.71%
|
|
-1.29%
|
-52.19%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,876
|
5,344
|
5,135
|
3,446
|
6,941
|
20,132
|
Enterprise Value (EV)
1 |
3,410
|
4,581
|
4,772
|
3,041
|
6,571
|
18,515
|
P/E ratio
|
-7.28
x
|
-10.2
x
|
-8.9
x
|
-5.73
x
|
-7.35
x
|
-14.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
35.2
x
|
46.5
x
|
46.7
x
|
31.9
x
|
-
|
-
|
EV / Revenue
|
31
x
|
39.8
x
|
43.4
x
|
28.2
x
|
-
|
-
|
EV / EBITDA
|
-6.4
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-14
x
|
-16.9
x
|
-14.1
x
|
-6.01
x
|
-17.3
x
|
-17.6
x
|
FCF Yield
|
-7.12%
|
-5.92%
|
-7.07%
|
-16.6%
|
-5.77%
|
-5.68%
|
Price to Book
|
9.21
x
|
8.05
x
|
21.7
x
|
7.78
x
|
28.4
x
|
10.2
x
|
Nbr of stocks (in thousands)
|
5,505
|
6,834
|
6,911
|
8,593
|
10,695
|
16,367
|
Reference price
2 |
704.0
|
782.0
|
743.0
|
401.0
|
649.0
|
1,230
|
Announcement Date
|
26/09/18
|
26/09/19
|
29/09/20
|
28/09/21
|
27/09/22
|
26/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
110
|
115
|
110
|
108
|
-
|
-
|
EBITDA
1 |
-533
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-539
|
-533
|
-566
|
-548
|
-846
|
-965
|
Operating Margin
|
-490%
|
-463.48%
|
-514.55%
|
-507.41%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-531
|
-455
|
-571
|
-530
|
-854
|
-1,243
|
Net income
1 |
-532
|
-456
|
-572
|
-531
|
-855
|
-1,244
|
Net margin
|
-483.64%
|
-396.52%
|
-520%
|
-491.67%
|
-
|
-
|
EPS
2 |
-96.69
|
-77.03
|
-83.52
|
-70.01
|
-88.26
|
-83.03
|
Free Cash Flow
1 |
-242.9
|
-271.1
|
-337.2
|
-505.9
|
-378.9
|
-1,052
|
FCF margin
|
-220.8%
|
-235.76%
|
-306.59%
|
-468.4%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/09/18
|
26/09/19
|
29/09/20
|
28/09/21
|
27/09/22
|
26/09/23
|
Fiscal Period: June |
2020 S1
|
2021 S1
|
2022 Q1
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 S1
|
2023 Q3
|
2024 Q1
|
2024 S1
|
---|
Net sales
|
55
|
55
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-267
|
-328
|
-195
|
-356
|
-222
|
-313
|
-551
|
-148
|
-194
|
-387
|
Operating Margin
|
-485.45%
|
-596.36%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-271
|
-309
|
-198
|
-359
|
-224
|
-322
|
-562
|
-148
|
-194
|
-393
|
Net income
1 |
-272
|
-310
|
-198
|
-359
|
-224
|
-322
|
-563
|
-148
|
-194
|
-393
|
Net margin
|
-494.55%
|
-563.64%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-39.80
|
-43.79
|
-22.48
|
-39.98
|
-22.94
|
-25.02
|
-40.12
|
-8.500
|
-11.19
|
-22.37
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/02/20
|
12/02/21
|
11/11/21
|
10/02/22
|
13/05/22
|
11/11/22
|
10/02/23
|
12/05/23
|
10/11/23
|
09/02/24
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
466
|
763
|
363
|
405
|
370
|
1,617
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-243
|
-271
|
-337
|
-506
|
-379
|
-1,052
|
ROE (net income / shareholders' equity)
|
-79%
|
-84.8%
|
-128%
|
-158%
|
-249%
|
-114%
|
ROA (Net income/ Total Assets)
|
-42.9%
|
-45.9%
|
-33.1%
|
-26.8%
|
-50.7%
|
-42%
|
Assets
1 |
1,240
|
994.5
|
1,729
|
1,983
|
1,686
|
2,965
|
Book Value Per Share
2 |
76.50
|
97.20
|
34.20
|
51.60
|
22.80
|
121.0
|
Cash Flow per Share
2 |
84.60
|
113.0
|
161.0
|
136.0
|
67.60
|
101.0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/09/18
|
26/09/19
|
29/09/20
|
28/09/21
|
27/09/22
|
26/09/23
|
|
1st Jan change
|
Capi.
|
---|
| -52.19% | 54.1M | | +8.05% | 72.03B | | -11.95% | 5.14B | | +51.87% | 4.6B | | +3.92% | 3.96B | | -14.26% | 2.5B | | +20.42% | 2.43B | | -23.94% | 2.32B | | +20.02% | 2.18B | | +3.66% | 1.72B |
Specialty & Advanced Pharmaceuticals
|